Cannasouth Limited

CBD

NZCBDE0009S6

Biotechnology & Medical Research

End-of-day quote New Zealand S.E. Other stock markets 19:00:00 2024-03-24 EDT			5-day change	1st Jan Change
0.098 ^NZD	+2.08%		-.--%	-26.32%

05-29	Cannasouth Sets Watershed Meeting for June 7	MT
04-15	Cannasouth Terminates COO	MT

Cannasouth Limited Approves Election of Christine Pears as Non-Executive Independent Director

July 01, 2021 at 04:30 pm

Cannasouth Limited approved election of Christine Pears as Non-executive Independent Director role on the board in the annual general meeting held on June 28, 2021.

Latest news about Cannasouth Limited

Cannasouth Sets Watershed Meeting for June 7	05-29	MT
Cannasouth Terminates COO	04-15	MT
New Zealand Shares Fall on Rate Cut Woes; Cannasouth's CEO Resigns	04-11	MT
Cannasouth CEO Resigns	04-10	MT
Cannasouth Enters Voluntary Administration, CFO Resigns	03-28	MT
Cannasouth Extends Trading Halt, Mulls Restructuring Options	03-27	MT
Cannasouth Shares Placed on Trading Halt	03-25	MT
Cannasouth Limited Reports Revenue Results for the Month of December 2023	01-22	CI
Cannasouth Issues NZ$1.1 Million Convertible Bonds	12-21	MT
Cannasouth Raises Over NZ$2 Million from Sale of Shares, Bonds	12-12	MT
Cannasouth Limited acquired Eqalis Group New Zealand Limited from Eqalis shareholders.	23-05-29	CI
Cannasouth Limited Auditor Raises 'Going Concern' Doubt	23-03-28	CI
Cannasouth Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-01	CI
Cannasouth Limited signed a binding term sheet to acquire Eqalis Group New Zealand Limited from Eqalis shareholders for NZD 44.4 million.	22-12-18	CI
Cannasouth Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-10	CI
Cannasouth Limited Auditor Raises 'Going Concern' Doubt	22-03-30	CI
Cannasouth Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-28	CI
Cannasouth Limited completed the acquisition of remaining 50% stake in Cannasouth Cultivation Limited from Aaron Craig.	21-11-29	CI
Cannasouth Limited Announces Unaudited Consolidated Earnings Results for the Six Months Ended 30 June 2021	21-08-30	CI
Cannasouth Limited completed the acquisition of remaining 40% stake in Midwest Pharmaceutics NZ Limited from Greenmeadows Health Limited and Mark Balchin.	21-08-01	CI
Cannasouth Limited signed an agreement to acquire remaining 50% stake in Cannasouth Cultivation Limited from Aaron Craig.	21-07-03	CI
Cannasouth Limited agreed to acquire remaining 40% of stake in Midwest Pharmaceutics NZ Limited from Greenmeadows Health Limited and Mark Balchin for NZD 1 million.	21-07-03	CI
Cannasouth Limited Approves Election of Christine Pears as Non-Executive Independent Director	21-07-01	CI
Cannasouth Limited Auditor Raises 'Going Concern' Doubt	21-03-29	CI
Cannasouth Limited Announces Unaudited Earnings Results for the Year Ended December 31, 2020	21-02-24	CI

Cannasouth Limited is a New Zealand-based biopharmaceutical company focused on medicinal cannabis. The Company is vertically integrated, with business activities ranging from the production and supply of cannabis flower, manufacturing of cannabis-based ingredients and finished dosage products. It also offers an online clinic, and related activities, such as research and development, marketing, and sales. The Company provides a range of imported, Cannasouth-branded medicinal cannabis products. Its subsidiaries include Eqalis Pharmaceuticals Limited, Eqalis Innovation Limited, Cannasouth Bioscience Limited, and Cannasouth Cultivation Limited.

Sector

Biotechnology & Medical Research

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CANNASOUTH LIMITED	-26.32%	19.87M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
BIO-TECHNE CORPORATION	+0.04%	12.16B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research